Kareem Saad

Most recently, Kareem served as Chief Transformation Officer at GeneDx, responsible for driving corporate strategy, corporate development, and emerging business initiatives to further accelerate the company’s growth. Prior to that, Kareem served as Chief Strategy Officer at Sema4, leading the development of their long term plan, spearheading their capital formation efforts and eventually helping to take the company public in 2021 before leading the merger with GeneDx to transform the company into a leading rare disease diagnostic testing company.

Prior to joining Sema4, Kareem was President and Chief Operating Officer at Apervita, Inc., overseeing its transformation to a product- and value-based care and quality measurement technology company. Kareem previously served as Chief Commercial Officer/EVP of Strategy and Business Development at SourceMed, a PE-backed healthcare IT and services company focused on delivering practice management technology solutions to the outpatient market, where he led a series of transactions that culminated in the sale and merger of the company with Surgical Information Systems.

Kareem also served as a Director in Dell’s Healthcare and Life Sciences division where he was responsible for managing a $180 million healthcare partner program. Before that, he held a number of executive roles in biotech and healthcare technology startups as well as leading the Information Based Medicine Commercial Group at IBM’s Healthcare Life Sciences group helping grow that business to $100 million in less than five years.

Kareem holds a BSc in Biochemistry and Molecular Biology with a minor in Computer Science from the University of British Columbia and an MBA with a concentration in Economics and Finance from the University of Chicago.